Cantor Fitzgerald reiterated their overweight rating on shares of Zimmer Biomet (NYSE:ZBH) in a research report report published on Friday.

Other equities analysts have also issued reports about the stock. Deutsche Bank upgraded shares of Zimmer Biomet from a hold rating to a buy rating and set a $128.00 target price on the stock in a report on Tuesday, November 14th. Edward Jones upgraded shares of Zimmer Biomet from a hold rating to a buy rating in a report on Thursday, November 9th. SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the company a buy rating in a report on Wednesday, November 1st. Jefferies Group reiterated a buy rating and issued a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. Finally, BMO Capital Markets reissued a buy rating and issued a $142.00 price target on shares of Zimmer Biomet in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Buy and an average target price of $137.42.

Zimmer Biomet (ZBH) opened at $126.22 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The firm has a market cap of $25,560.00, a PE ratio of 39.32, a price-to-earnings-growth ratio of 1.96 and a beta of 1.15. Zimmer Biomet has a fifty-two week low of $104.77 and a fifty-two week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.79 earnings per share. equities research analysts predict that Zimmer Biomet will post 8.03 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Stockholders of record on Friday, December 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 29.91%.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. CWA Asset Management Group LLC increased its stake in Zimmer Biomet by 1.8% during the 2nd quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock worth $251,000 after buying an additional 34 shares during the period. Advisory Services Network LLC increased its stake in Zimmer Biomet by 1.0% during the 2nd quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock worth $474,000 after buying an additional 37 shares during the period. Sandy Spring Bank increased its stake in Zimmer Biomet by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 66 shares during the period. Financial Counselors Inc. increased its stake in Zimmer Biomet by 1.2% during the 2nd quarter. Financial Counselors Inc. now owns 6,215 shares of the medical equipment provider’s stock worth $798,000 after buying an additional 73 shares during the period. Finally, Synovus Financial Corp increased its stake in Zimmer Biomet by 6.3% during the 2nd quarter. Synovus Financial Corp now owns 2,288 shares of the medical equipment provider’s stock worth $293,000 after buying an additional 135 shares during the period. 85.92% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/01/09/zimmer-biomet-zbh-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related stocks with our FREE daily email newsletter.